Answer first: semaglutide is the most established GLP-1-only option, tirzepatide is the approved dual GIP/GLP-1 option with stronger Phase 3 weight-loss results, and retatrutide is the investigational triple GIP/GLP-1/glucagon agonist with the largest reported Phase 3 obesity topline result so far. That does not mean retatrutide is the practical winner today. It is not FDA-approved, has no post-market safety record, and has not been tested head-to-head against tirzepatide or semaglutide in a completed Phase 3 outcomes trial.
This is a YMYL educational guide, not medical advice and not a dosing or protocol page. The percentages below come from different trials with different durations, populations, trial-arm exposures, and background interventions. They help frame the evidence landscape; they should not be read as a guaranteed ranking for any individual.
Side-by-side comparison
| Compare | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Mechanism | Selective GLP-1 receptor agonist. | Dual GIP and GLP-1 receptor agonist. | Triple GIP, GLP-1, and glucagon receptor agonist. |
| FDA status | FDA-approved prescription medication for type 2 diabetes, chronic weight management under the weight-management label, and selected cardiovascular-risk indications under approved labeling. | FDA-approved prescription medication for type 2 diabetes, chronic weight management, and moderate-to-severe obstructive sleep apnea in adults with obesity under the sleep-apnea indication. | Investigational. Not FDA-approved for any indication as of June 2026. |
| Weight-loss efficacy | STEP program: about 15% to 17% mean body-weight reduction in major obesity trials, depending on trial design and population. | SURMOUNT-1: up to 22.5% mean body-weight reduction at 72 weeks in adults with obesity or overweight without diabetes. | TRIUMPH-1 topline: 28.3% mean body-weight reduction at 80 weeks in the highest trial arm; 45.3% reached at least 30% weight loss. Full peer-reviewed Phase 3 publication was still pending at the May 2026 topline stage. |
| Route | Subcutaneous injection for the obesity and injectable diabetes products; oral tablet formulation exists for type 2 diabetes. | Subcutaneous injection. | Subcutaneous injection in clinical trials. |
| Key trials | STEP 1, STEP 3, STEP 4, STEP 5 for weight management; SUSTAIN and PIONEER programs for type 2 diabetes; SELECT for cardiovascular outcomes in obesity/overweight with established cardiovascular disease. | SURMOUNT-1 and SURMOUNT-5 for obesity; SURMOUNT-OSA for obstructive sleep apnea in adults with obesity; SURPASS program for type 2 diabetes. | TRIUMPH-1 Phase 3 obesity topline reported May 2026; Phase 2 NEJM obesity study; broader TRIUMPH/TRANSCEND programs for obesity, type 2 diabetes, and MASH development. |
Semaglutide, tirzepatide, and retatrutide compared across mechanism, regulatory status, weight-loss evidence, route, and key trials. Cross-trial figures are not head-to-head results.
Bottom line: which one is strongest on evidence today?
If the question is regulatory maturity and long-term evidence, semaglutide has the deepest established track record: large Phase 3 programs, cardiovascular outcomes data, approved products, and broad post-market experience. If the question is approved weight-loss efficacy, tirzepatide currently leads the approved options, with SURMOUNT-1 reporting up to 22.5% mean weight loss and SURMOUNT-5 directly outperforming the comparator semaglutide arm. If the question is highest reported trial weight-loss signal, retatrutide leads on the May 2026 TRIUMPH-1 topline with 28.3% mean weight loss at 80 weeks and 45.3% of participants reaching at least 30% weight loss in the highest trial arm.
Those are three different answers because the evidence question is three different questions: established safety record, approved efficacy, and investigational ceiling. For patient-level decisions, only the first two are currently prescription realities in the United States. Retatrutide remains a clinical-trial drug until regulators review a full submission and approve it.
Why mechanism matters: one receptor, two receptors, three receptors
Semaglutide is the cleanest mechanistic anchor: it acts as a GLP-1 receptor agonist. GLP-1 receptor activation increases glucose-dependent insulin secretion, suppresses glucagon when glucose is elevated, slows gastric emptying, and acts on brain appetite circuits to increase satiety. This mechanism explains both the metabolic benefits and the common gastrointestinal adverse effects.
Tirzepatide adds GIP receptor agonism to GLP-1 receptor agonism. The GIP component appears to add effects on insulin secretion, adipose tissue metabolism, and central appetite regulation. Clinically, that dual-receptor design translated into larger average weight loss than semaglutide in major trials, including a direct semaglutide comparator study in obesity.
Retatrutide adds glucagon receptor agonism on top of GIP and GLP-1. Glucagon receptor activation can increase energy expenditure and hepatic fat mobilization, but it also raises theoretical questions around heart rate, glycemic effects, and long-term cardiovascular outcomes. The triple-agonist design is why the efficacy signal is so large, but it is also why mature safety and outcomes data matter before treating it like an approved alternative.
Weight-loss numbers: useful signal, imperfect comparison
The headline figures are real but easy to misuse. Semaglutide's STEP program established roughly 15% to 17% mean weight loss in major obesity trials. Tirzepatide's SURMOUNT-1 reported up to 22.5% mean weight loss at 72 weeks. Retatrutide's TRIUMPH-1 May 2026 topline reported 28.3% mean weight loss at 80 weeks in the highest trial arm, with 45.3% of participants achieving at least 30% weight loss.
The caveat: these figures are not from one head-to-head three-arm trial. Trial duration differs: STEP studies often used 68-week or related designs, SURMOUNT-1 used 72 weeks, and TRIUMPH-1 used 80 weeks. Eligibility criteria, baseline weights, diabetes status, adherence patterns, retention, lifestyle programs, estimands, and trial-arm exposures differ too. Cross-trial ranking is useful for understanding why the field moved from GLP-1 to dual agonism to triple agonism, but it cannot predict what one person will lose on one medication.
FDA status and access: approved options versus investigational drug
Semaglutide and tirzepatide are FDA-approved prescription medications under specific labels. They can be prescribed by qualified clinicians when a patient fits an approved indication or when a clinician determines an off-label use is medically appropriate under ordinary prescribing rules. Their labels, contraindications, warnings, and post-market surveillance systems are part of the regulatory package.
Retatrutide is different. It is not FDA-approved, not a prescription product, and not legally interchangeable with semaglutide or tirzepatide. Access outside clinical trials or regulator-authorized programs is not the same as medical access. Research-chemical products marketed as retatrutide are not FDA-reviewed for identity, purity, potency, sterility, or safety. This guide does not endorse buying or using them.
How this guide reuses the pairwise evidence
The pairwise pages answer narrower questions: semaglutide vs tirzepatide compares GLP-1-only versus approved dual incretin therapy; retatrutide vs tirzepatide compares investigational triple agonism against the approved dual agonist; retatrutide vs semaglutide compares the highest-profile pipeline triple agonist against the established GLP-1 market leader.
This page exists because the hottest search intent is broader than pairwise schema: users want the whole GLP-1 escalation ladder in one place. The correct answer is not simply 'retatrutide wins.' The better answer is: semaglutide wins on history and outcomes depth, tirzepatide wins among approved drugs on average weight-loss magnitude, and retatrutide currently wins on investigational Phase 3 topline efficacy while losing on approval status and long-term certainty.
Frequently asked questions
Retatrutide has the largest reported obesity-trial topline signal among the three, with TRIUMPH-1 reporting 28.3% mean weight loss at 80 weeks and 45.3% of participants reaching at least 30% weight loss in the highest trial arm. But it is not FDA-approved, has no post-market safety record, and has not completed a Phase 3 head-to-head outcomes comparison against tirzepatide or semaglutide. It is more accurate to call it the strongest investigational efficacy signal, not the best current clinical option.
Semaglutide has the longest and deepest evidence record, including STEP weight-management trials, SUSTAIN and PIONEER diabetes trials, SELECT cardiovascular outcomes data, and extensive post-market use. Tirzepatide has stronger approved weight-loss efficacy in SURMOUNT trials. Retatrutide has the highest reported Phase 3 obesity topline efficacy but remains investigational with a less mature evidence package.
No. Semaglutide's 15-17% range comes from STEP obesity trials, tirzepatide's 22.5% figure comes from SURMOUNT-1, and retatrutide's 28.3% figure comes from the May 2026 TRIUMPH-1 topline. Different trial durations, populations, endpoints, and designs limit direct comparison. These numbers are useful context, not a guaranteed ranking for individual outcomes.
Semaglutide and tirzepatide are FDA-approved prescription medications under specific labels. Semaglutide has approved products for type 2 diabetes, chronic weight management, and selected cardiovascular-risk indications. Tirzepatide has approved products for type 2 diabetes, chronic weight management, and obstructive sleep apnea in adults with obesity. Retatrutide is investigational and is not FDA-approved as of June 2026.
No. PeptaHub does not provide dosing, titration, or protocol instructions for GLP-1 drugs or investigational peptides in this guide. These are prescription or investigational medical products, and dosing decisions belong to qualified clinicians within approved labeling or clinical-trial protocols.